David R. Gandara, M.D.

Clinical/Research Interests

Dr. Gandara's research interests focus on developmental therapeutics of new anti-cancer agents as well as preclinical modeling and clinical research in lung cancer. He is the principal investigator on an Early Therapeutics award from the National Cancer Institute (NCI), where he leads an interdisciplinary team of clinical oncologists, pharmacologists, molecular biologists and statisticians in developing new anti-cancer agents in a variety of novel drug classes. He also leads a multi-specialty team in the Southwest Oncology Group (SWOG), an NCI-funded national clinical research organization, in studies related to improving therapies for lung cancer and developing predictive biomarkers of therapeutic efficacy. Dr. Gandara is also the UC Davis principal investigator for a multi-institutional collaboration (iGXT: integrated Genetically-engineered mouse models, patient-derived Xenografts, and Clinical Trials) between the NCI Center for Advanced Preclinical Research (CAPR) and Jackson Laboratory, an NCI-designated basic cancer center. The goal of this iGXT project is to develop better preclinical models to optimize cancer drug development and speed the transition to personalized cancer therapy.

Title:

Professor, Senior Advisor to Director, UC Davis Cancer Center, Director, Thoracic Oncology Program

Specialty:

Hematology and Oncology, Cancer, Internal Medicine

Center/Program Affiliation:

UC Davis Comprehensive Cancer Center

Address:

UC Davis Comprehensive Cancer Center
4501 X St., Suite 3016
Sacramento, CA 95817

Phone:

(916) 734-5959

Education:

University of Texas Medical Branch at Galveston
Galveston, Texas
M.D. 1973

University of Texas
Austin, Texas
B.A. 1969

Internships:

Madigan Army Medical Center
Tacoma, Washington
1973-74

Residency:

Madigan Army Medical Center
Tacoma, Washington
1974-76
Internal Medicine

Fellowships:

Letterman Army Medical Center
San Francisco, California
1976-78
Hematology/Oncology

Board Certifications:

American Board of Internal Medicine, Medical Oncology, 1979
American Board of Internal Medicine, 1976

Professional Memberships:

Alpha Omega Alpha
American Medical Association
American Society for Cancer Research
American Society of Hematology
Fellow, American College of Physicians
Multinational Association for Supportive Care in Cancer
Secretary-Treasurer and member of the Board of Directors of the American Society of Clinical Oncology (ASCO)
Secretary-Treasurer and member of the Board of Directors of the International Association for the Study of Lung Cancer (IASLC)

Honors and Awards:

U.S. News Top Doctors, 2011-2012
America's Top Doctors, 2001-2011
Top Cancer Specialists for Women: Lung Cancer, Good Housekeeping Magazine, 1999
Oettinger Memorial Award: Lung Cancer Research, 1998
Semlar Visiting Professorship, Boston University, 1993
Outstanding Attending Physician, Martinez VA Medical Center, 1987
Outstanding Resident Teacher, Madigan Army Medical Center, 1974

Select Recent Publications:

Semrad TJ, Gandara DR, Lara PN Jr. Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol. 2011 Mar;3(2):95-100.

Ramalingam SS, Davies AM, Longmate J, Edelman MJ, Lara PN Jr, Vokes EE, Villalona-Calero M, Gitlitz B, Reckamp K, Salgia R, Wright JJ, Belani CP, Gandara DR. Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003). J Thorac Oncol. 2011 Oct;6(10):1741-5.

Holland WS, Tepper CG, Pietri JE, Chinn DC, Gandara DR, Mack PC, Lara PN Jr. Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy. Cancer Chemother Pharmacol. 2011 Jun 5.

Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug;6(8):1418-25.

Somlo G, Lashkari A, Bellamy W, Zimmerman TM, Tuscano JM, O'Donnell MR, Mohrbacher AF, Forman SJ, Frankel P, Chen HX, Doroshow JH, Gandara DR. Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial. Br J Haematol. 2011 Aug;154(4):533-5. doi: 10.1111/j.1365-2141.2011.08623.x. Epub 2011 Apr 26.

Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN Jr. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct;16(5):494-9. Epub 2011 Mar 23.

Lara PN Jr, Longmate J, Reckamp K, Gitlitz B, Argiris A, Ramalingam S, Belani CP, Mack PC, Lau DH, Koczywas M, Wright JJ, Shepherd FA, Leighl N, Gandara DR.Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. Clin Lung Cancer. 2011 Jan;12(1):33-7.

Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011 Mar 1;29(7):909-16. Epub 2011 Jan 31.

Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I, Nademanee A, Forman SJ, Gandara D, Newman E. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol. 2011 Mar 20;29(9):1198-203. Epub 2011 Feb 7.

Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EM. A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol. 2011 Mar;6(3):598-601.